Vitiligo Pharmaceutical Research status

Written By The Vitiligo Way .

While we don’t believe in magic creams for vitiligo It is always nice to see developments and new ideas coming from the pharmaceutical industry. The new drugs and ingredients could help investigators to explore what things may or may not work in their own case even if they do not try the drug itself. Additionally real knowledge of the ingredients helps to be better informed in general and identify unsafe options independently. These are the current research drugs to be aware of and further investigate in terms of safety and potential for use in combination with other therapies.

  • Afamelanotide / Clinuvel [Phase III]

  • Ritlecitinib / Pfizer [Phase III]

  • Upadacitinib / AbbVie [Phase III]

  • Povorcitinib / Incyte [Phase III]

  • AMG-714 / Amgen [Phase II]

  • VYN201 / Vyne Therapeutics [Phase II]

  • Cerdulatinib / Dermavant [Phase II]

  • Crisaborole / Pfizer [Phase II]

  • EB-06 / Edesa Biotech [Phase II]

  • Ordesekimab / Amgen [Phase II]

  • AS012 / Sun Pharmaceutical [Phase II]

  • SHR0302 Base / Jiangsu HengRui Medicine [Phase II]

  • FB102 / Forte Biosciences [Phase I]

  • TEV-53408 / Teva Pharmaceutical [Phase I]

  • DR-01 / Dren Bio [Phase I]

The Vitiligo Way .
Next

Vitiligo Database Proper reaches 100 entries